Table of Contents Table of Contents
Previous Page  88 / 90 Next Page
Information
Show Menu
Previous Page 88 / 90 Next Page
Page Background

86

NCCN Guidelines for Patients

®

:

Thyroid Cancer, Version 1.2017

Index

Index

anaplastic thyroid cancer

17–18, 25, 27, 31–33, 35,

37, 64–66

biopsy

10, 12, 16, 18–22, 28, 31, 40, 43–44, 56, 64

blood test

11–12, 15–16, 19, 22, 25, 28, 34, 46, 49,

51, 54, 61–62, 64

chemotherapy

34–35, 37, 53, 61, 64–65

clinical trial

28, 35–37, 53, 61, 64–65, 70, 72

complementary and alternative medicine

37

computed tomography

(CT)

11, 17, 28, 33, 39, 46,

48, 50, 60, 64–65

diagnosis

10, 15–16, 18, 22, 25, 27, 64, 66, 73

follicular thyroid cancer

26, 31–32, 37, 42–43

Hürthle cell thyroid cancer

18, 20–21, 26, 34,

42–44, 54

imaging test

11–12, 17, 19–22, 28, 39, 45, 47–52, 54,

59, 61

magnetic resonance imaging (MRI)

17, 28, 39, 56,

60

medical history

15, 22, 28

medullary thyroid cancer

10, 12, 16, 27, 35, 56–57,

59, 61–62

metastases

47, 50, 53, 61, 66

molecular test

18, 21, 42, 44, 56–57

NCCN Member Institutions

84

NCCN Panel Members

83

neck dissection

31, 57–59

papillary thyroid cancer

10, 12, 39–41, 43, 54

parathyroid gland

8–9, 58–59

pathology report

18

physical exam

15, 28, 48–49, 51, 54

postiron emission tomography (PET)

17, 33, 52,

64–65

radioiodine imaging

19, 28, 45, 50, 52

radioactive idoine (RAI) therapy

32–33, 42, 45–49,

52–54

radiation therapy

28, 33, 37, 51, 57–59, 51, 65–66

recurrence

16, 34, 50, 52, 61

side effect

31–37, 71

stage

10, 25–29, 50, 64, 66, 73

surgery

10, 16–18, 22, 28–33, 35, 37, 39–40, 42–47,

49, 52–54, 56–62, 64–66

targeted therapy

35–37

thyroid

8–13, 15–22, 25–29, 31–35, 37, 39–49,

52–54, 56–62, 64–66

thyroid hormone replacement therapy

34

thyroid nodule

11, 16, 18–20, 22, 31

treatment plan

25, 28, 33, 39, 56, 64, 68, 73

ultrasound

11, 16–21, 28, 39, 46, 50, 52, 56, 58–60,

64